

Pierfranco Conte

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4890194/pierfranco-conte-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

364
papers

19,852
citations

65
h-index

132
g-index

387
ext. papers

23,603
ext. citations

5.3
avg, IF

6.27
L-index

#	Paper	IF	Citations
364	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.. <i>EBioMedicine</i> , 2022 , 75, 103801	8.8	3
363	Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2 ^{low} breast cancer. <i>Cancer Research</i> , 2022 , 82, GS2-01-GS2-01	10.1	0
362	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.. <i>New England Journal of Medicine</i> , 2022 , 386, 942-950	59.2	18
361	Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study.. <i>European Journal of Cancer</i> , 2022 , 167, 81-91	7.5	0
360	The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies.. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 169, 103567	7	13
359	Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. <i>Clinical Cancer Research</i> , 2021 ,	12.9	6
358	Evolution of HER2-low expression from primary to recurrent breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 137	7.8	4
357	ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 625636	5.3	2
356	Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covid19 study. <i>European Journal of Cancer</i> , 2021 , 147, 120-127	7.5	8
355	Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
354	Anticancer innovative therapy congress: Highlights from the 10th anniversary edition. <i>Cytokine and Growth Factor Reviews</i> , 2021 , 59, 1-8	17.9	2
353	Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in -Mutated Non-small Cell Lung Cancer: A Case Report. <i>Frontiers in Medicine</i> , 2021 , 8, 570921	4.9	0
352	Patient-Reported Outcomes in Patients With -Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2005-2015	2.2	7
351	Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 163, 103378	7	2
350	Real-world data on treatment outcomes in -mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. <i>Future Oncology</i> , 2021 , 17, 2513-2527	3.6	0
349	Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model. <i>Thoracic Cancer</i> , 2021 , 12, 13-20	3.2	4
348	Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. <i>Cancers</i> , 2021 , 13,	6.6	4

347	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. <i>Clinical Cancer Research</i> , 2021 , 27, 3116-3125	12.9	3
346	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 12	7.8	2
345	Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe. <i>Breast</i> , 2021 , 55, 79-90	3.6	5
344	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021 , 13,	6.6	4
343	MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR, HER2-Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 5801-5809 ⁰	12.9	0
342	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. <i>European Journal of Cancer</i> , 2021 , 153, 133-141	7.5	4
341	Non-Small-Cell Lung Cancer: Real-World Cost Consequence Analysis. <i>JCO Oncology Practice</i> , 2021 , 17, e1085-e1093	2.3	1
340	Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINTenance Afinitor) trial. <i>European Journal of Cancer</i> , 2021 , 154, 21-29	7.5	1
339	Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification. <i>Cytokine</i> , 2021 , 146, 155622	4	0
338	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 1089-1097	9.7	25
337	Tepotinib in Non-Small-Cell Lung Cancer with Exon 14 Skipping Mutations. <i>New England Journal of Medicine</i> , 2020 , 383, 931-943	59.2	201
336	Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. <i>European Journal of Cancer</i> , 2020 , 136, 7-15	7.5	13
335	Real-World Evidence in Oncology: Opportunities and Limitations. <i>Oncologist</i> , 2020 , 25, e746-e752	5.7	21
334	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. <i>Breast</i> , 2020 , 50, 56-63	3.6	3
333	Olaparib for advanced breast cancer. <i>Future Oncology</i> , 2020 , 16, 717-732	3.6	6
332	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020 , 12,	6.6	3
331	Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. <i>Cancer Treatment Reviews</i> , 2020 , 87, 102031	14.4	37
330	Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. <i>Future Oncology</i> , 2020 , 16, 129-145	3.6	4

329	Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 564915	5.3	4
328	Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases. <i>ESMO Open</i> , 2020 , 5, e000843	6	5
327	Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer. <i>Oncologist</i> , 2020 , 25, e1355-e1362	5.7	4
326	mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	9
325	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , 2020 , 21, 1455-1464	21.7	20
324	Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2 Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. <i>Clinical Cancer Research</i> , 2020 , 26, 5843-5851	12.9	17
323	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 46-54	9.7	48
322	The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 116-124	13.4	289
321	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. <i>Clinical Lung Cancer</i> , 2020 , 21, 1-14.e3	4.9	10
320	Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer. <i>Cancer</i> , 2020 , 126, 3132-3139	6.4	7
319	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. <i>European Journal of Cancer</i> , 2019 , 120, 20-30	7.5	35
318	OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. <i>Annals of Oncology</i> , 2019 , 30, 558-566	10.3	240
317	Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2019 , 380, 1929-1940	59.2	853
316	A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology. <i>Scientific Reports</i> , 2019 , 9, 7154	4.9	34
315	LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	20
314	Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events. <i>PLoS ONE</i> , 2019 , 14, e0213934	3.7	5
313	Neoplastic Pericardial Effusion: A Monocentric Retrospective Study. <i>Journal of Palliative Medicine</i> , 2019 , 22, 691-695	2.2	6
312	Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 138, 87-103	7	8

311	Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. <i>Scientific Reports</i> , 2019 , 9, 1788	4.9	36
310	Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center. <i>Journal of Women's Health</i> , 2019 , 28, 544-550	3	3
309	Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE. <i>Cancer</i> , 2019 , 125, 3974-3984	6.4	31
308	BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis. <i>Breast</i> , 2019 , 47, 77-84	3.6	9
307	From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for -Positive Non-Small Cell Lung Cancer (MOST Study). <i>Oncologist</i> , 2019 , 24, e318-e326	5.7	3
306	Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer. <i>PeerJ</i> , 2019 , 7, e7232	3.1	17
305	De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. <i>Annals of Oncology</i> , 2019 , 30, 921-926	10.3	38
304	Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. <i>Oncologist</i> , 2019 , 24, 1128-1136	5.7	68
303	Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study. <i>Oncologist</i> , 2019 , 24, 1424-1431	5.7	11
302	HER2-Positive Early Breast Cancer 2019 , 371-382		
301	MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. <i>Theranostics</i> , 2019 , 9, 436-448	12.1	25
300	Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. <i>Annals of Oncology</i> , 2019 , 30, 418-423	10.3	40
299	Olaparib for the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 519-530	3.5	25
298	External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience. <i>Breast</i> , 2018 , 37, 36-41	3.6	19
297	PARP Inhibitors in Breast Cancer: Why, How, and When?. <i>Breast Care</i> , 2018 , 13, 216-219	2.4	2
296	Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 127-134	4.4	62
295	First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer. <i>Oncologist</i> , 2018 , 23, 297-305	5.7	7
294	Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. <i>Annals of Oncology</i> , 2018 , 29, 2328-2333	10.3	77

293	Immune characterization of breast cancer metastases: prognostic implications. <i>Breast Cancer Research</i> , 2018 , 20, 62	8.3	32
292	Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 128, 19-29	7	7
291	Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 141-148	2.2	246
290	LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. <i>Clinical Cancer Research</i> , 2017 , 23, 3316-3324	12.9	28
289	Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patients. <i>Nuclear Medicine Communications</i> , 2017 , 38, 537-545	1.6	7
288	Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation. <i>Breast</i> , 2017 , 35, 21-26	3.6	12
287	Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. <i>New England Journal of Medicine</i> , 2017 , 377, 523-533	59.2	1405
286	A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study). <i>Clinical Colorectal Cancer</i> , 2017 , 16, 410-415.e1	3.8	6
285	Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials. <i>Breast Cancer Research and Treatment</i> , 2017 , 163, 295-302	4.4	13
284	Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 119, 30-39	7	29
283	Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome. <i>Journal of Neuro-Oncology</i> , 2017 , 131, 369-376	4.8	6
282	Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. <i>Oncotarget</i> , 2017 , 8, 32626-32638 ¹⁴	3.3	14
281	GD2 expression in breast cancer. <i>Oncotarget</i> , 2017 , 8, 31592-31600	3.3	25
280	Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2017 , 37, 3723-3728	2.3	3
279	Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 97, 220-30	7	35
278	The European Cancer Patient's Bill of Rights, update and implementation 2016. <i>ESMO Open</i> , 2016 , 1, e000127	6	25
277	A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e63-e64	8.9	11
276	The impact of adjuvant endocrine therapy in early breast cancer on quality-of-life: an overview of prospective trials. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016 , 1, 111-120		2

275	5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 117-26	4.4	9
274	Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman. <i>Lung Cancer</i> , 2016 , 96, 52-5	5.9	7
273	Whole exome sequencing of rare aggressive breast cancer histologies. <i>Breast Cancer Research and Treatment</i> , 2016 , 156, 21-32	4.4	26
272	Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 100, 57-68	7	13
271	A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 295-302	4.4	12
270	Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization. <i>Oncotarget</i> , 2016 , 7, 25050-63	3.3	6
269	¹⁸ F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis. <i>Current Radiopharmaceuticals</i> , 2016 , 9, 244-257	1.8	29
268	Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched with Patients Treated with Parenteral Chemotherapy. <i>Anticancer Research</i> , 2016 , 36, 6541-6546	2.3	2
267	Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment. <i>OncoTargets and Therapy</i> , 2016 , 9, 3671-81	4.4	2
266	Cancer Control in Central and Eastern Europe. <i>Oncologist</i> , 2016 , 21, 1161-1162	5.7	10
265	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1738-1748	59.2	975
264	The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. <i>Cell Adhesion and Migration</i> , 2015 , 9, 14-21	3.2	37
263	Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature. <i>Cancer Biology and Therapy</i> , 2015 , 16, 1128-35	4.6	19
262	Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 1648-1655	8.8	7
261	Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas. <i>Stem Cells</i> , 2015 , 33, 859-69	5.8	35
260	Mesenchymal progenitors aging highlights a miR-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis. <i>Stem Cells</i> , 2015 , 33, 939-50	5.8	45
259	Complete response to weekly carboplatin-docetaxel chemotherapy in a 91-year-old woman with anaplastic thyroid cancer. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2015 , 36, 268-72	2.8	2
258	Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. <i>Trials</i> , 2015 , 16, 575	2.8	20

257	Impressive Response to Dose-Dense Chemotherapy in a Patient with NUT Midline Carcinoma. <i>American Journal of Case Reports</i> , 2015 , 16, 424-9	1.3	9
256	Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature. <i>American Journal of Case Reports</i> , 2015 , 16, 782-9	1.3	7
255	Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer. <i>Tumori</i> , 2015 , 101, 506-10	1.7	8
254	Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. <i>Annals of Oncology</i> , 2015 , 26, 1698-704	10.3	183
253	Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. <i>Oncologist</i> , 2015 , 20, 1001-10	5.7	59
252	Preoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be study. <i>Annals of Surgical Oncology</i> , 2015 , 22, 2881-7	3.1	12
251	Abstract P5-19-02: Everolimus in combination with exemestane in hormone receptor-positive locally advanced or metastatic breast cancer (BC) patients progressing on prior non-steroidal AI (NSAIs): Ballet study (CRAD001YIC04) 2015 ,		2
250	A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing. <i>Oncotarget</i> , 2015 , 6, 24884-94	3.3	47
249	MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data. <i>Oncotarget</i> , 2015 , 6, 42053-66	3.3	9
248	Targeted Therapies for HER2-positive Breast Cancer. <i>Current Clinical Pathology</i> , 2015 , 57-72	0.1	
247	Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer. <i>Anticancer Research</i> , 2015 , 35, 2183-9	2.3	2
246	Targeting bone metastatic cancer: Role of the mTOR pathway. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1845, 248-54	11.2	21
245	Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1050-7	2.2	40
244	Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. <i>Oncologist</i> , 2014 , 19, 805-137	1.3	93
243	Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 1041-50	3.5	4
242	A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 903-105	3.5	5
241	Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 399-410	3.5	59
240	A Bill of Rights for patients with cancer in Europe. <i>Lancet Oncology, The</i> , 2014 , 15, 258-60	21.7	19

239	Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. <i>Annals of Oncology</i> , 2014 , 25, 611-618	10.3	267
238	A catalyst for change: the European cancer Patient's Bill of Rights. <i>Oncologist</i> , 2014 , 19, 217-24	5.7	24
237	Squamous cell carcinoma of the oral cavity in a woman with a 9-year history of ovarian cancer: is exposure to pegylated liposomal Doxorubicin a factor?. <i>Oncologist</i> , 2014 , 19, 429	5.7	6
236	Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials. <i>Cancer Treatment Reviews</i> , 2014 , 40, 847-56	14.4	15
235	Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. <i>Digestive and Liver Disease</i> , 2014 , 46, 182-6	3.3	34
234	Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact. <i>Anticancer Research</i> , 2014 , 34, 3657-62	2.3	8
233	Relapsed triple-negative breast cancer: challenges and treatment strategies. <i>Drugs</i> , 2013 , 73, 1257-65	12.1	34
232	The Future of Chemotherapy in the Era of Personalized Medicine. <i>Current Breast Cancer Reports</i> , 2013 , 5, 57-68	0.8	2
231	Surgical margins in head and neck squamous cell carcinoma: what is 'close'?. <i>European Archives of Oto-Rhino-Laryngology</i> , 2013 , 270, 2603-9	3.5	61
230	Adipose stromal/stem cells assist fat transplantation reducing necrosis and increasing graft performance. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013 , 18, 1274-89	5.4	46
229	Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. <i>European Journal of Cancer</i> , 2013 , 49, 3831-8	7.5	38
228	A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 411-9	4.4	23
227	Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades. <i>Archives of Gynecology and Obstetrics</i> , 2013 , 288, 1203-12	2.5	8
226	Fatal oxaliplatin-induced thrombotic thrombocytopenic purpura: a case report. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 294-6	3.8	7
225	MSC and Tumors: Homing, Differentiation, and Secretion Influence Therapeutic Potential. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2013 , 130, 209-66	1.7	36
224	Gene expression profiling in breast cancer: a clinical perspective. <i>Breast</i> , 2013 , 22, 109-120	3.6	56
223	Effects of sulfonylureas on tumor growth: a review of the literature. <i>Oncologist</i> , 2013 , 18, 1118-25	5.7	38
222	Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. <i>International Journal of Cancer</i> , 2013 , 132, E58-65	7.5	9

221	Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood. <i>BioMed Research International</i> , 2013 , 2013, 901821	3	60
220	Body mass index and prognosis of metastatic breast cancer patients receiving first-line chemotherapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 1862-7	4	17
219	Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. <i>Annals of Oncology</i> , 2013 , 24, 2990-4	10.3	69
218	Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. <i>Annals of Oncology</i> , 2013 , 24, 101-8	10.3	107
217	Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. <i>Breast</i> , 2012 , 21, 20-6	3.6	24
216	Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. <i>BJU International</i> , 2012 , 110, 692-8	5.6	37
215	Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer. <i>Cancer</i> , 2012 , 118, 461-8	6.4	18
214	Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1594-600	2.2	189
213	Management and treatment of triple-negative breast cancer patients from the NEMESI study: an Italian experience. <i>European Journal of Cancer</i> , 2012 , 48, 642-7	7.5	10
212	Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 395-406	4	57
211	Survival in Patients with Newly Diagnosed Conventional Glioblastoma: A Modified Prognostic Score Based on a Single-Institution Series. <i>Tumori</i> , 2012 , 98, 756-761	1.7	3
210	The next generation of biologic agents: therapeutic role in relation to existing therapies in metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2012 , 12, 157-66	3	6
209	Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1989-95	2.2	284
208	Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. <i>Journal of Clinical Pathology</i> , 2012 , 65, 503-6	3.9	10
207	Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, e76-8	2.2	101
206	European Perspectives: A Dialogue with the European Oncology Community. <i>Oncologist</i> , 2012 , 17,	5.7	78
205	Survival in patients with newly diagnosed conventional glioblastoma: a modified prognostic score based on a single-institution series. <i>Tumori</i> , 2012 , 98, 756-61	1.7	3
204	FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. <i>British Journal of Cancer</i> , 2011 , 104, 1079-84	8.7	34

203	Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer. <i>Annals of Surgical Oncology</i> , 2011 , 18, 2150-7	3.1	12
202	Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 755-65	4.4	22
201	Bevacizumab treatment for advanced breast cancer. <i>Oncologist</i> , 2011 , 16, 1684-97	5.7	15
200	Timing for starting second-line therapy in recurrent ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 49-55	3.5	8
199	Biomarkers predicting clinical benefit: fact or fiction?. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 63-6	4.8	6
198	International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 147-51	4.8	55
197	Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers. <i>American Journal of Cancer Research</i> , 2011 , 1, 787-805	4.4	22
196	Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. <i>British Journal of Cancer</i> , 2010 , 102, 68-72	8.7	173
195	Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. <i>British Journal of Cancer</i> , 2010 , 103, 1019-24	8.7	39
194	Predictive and Prognostic Role of P53 According to Tumor Phenotype in Breast Cancer Patients Treated with Preoperative Chemotherapy: A Single-Institution Analysis. <i>International Journal of Biological Markers</i> , 2010 , 25, 104-111	2.8	7
193	An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. <i>Annals of Oncology</i> , 2010 , 21, 474-480	10.3	59
192	Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3256-63	2.2	181
191	Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1138-44	2.2	496
190	GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. <i>Cytotherapy</i> , 2010 , 12, 466-77	4.8	50
189	Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. <i>Cancer Treatment Reviews</i> , 2010 , 36 Suppl 3, S62-6	14.4	35
188	Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. <i>Cancer Research</i> , 2010 , 70, 3718-29	10.1	195
187	Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 122, 181-8	4.4	189
186	A computational workflow for the design of irreversible inhibitors of protein kinases. <i>Journal of Computer-Aided Molecular Design</i> , 2010 , 24, 183-94	4.2	9

185	Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies. <i>Cancer Genetics and Cytogenetics</i> , 2010 , 200, 1-7		2
184	Achievements and unmet needs in the management of advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2010 , 117, 152-8	4.9	68
183	Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. <i>Oncologist</i> , 2009 , 14, 645-56	5.7	80
182	The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients. <i>Cancer Biology and Therapy</i> , 2009 , 8, 1456-8	4.6	2
181	Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. <i>Annals of Oncology</i> , 2009 , 20, 469-74	10.3	73
180	A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. <i>Annals of Oncology</i> , 2009 , 20, 1193-8	10.3	61
179	Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4642-8	2.2	93
178	Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009 , 115, 131-6	4.4	10
177	All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial. <i>British Journal of Cancer</i> , 2009 , 101, 232-7	8.7	34
176	Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 73, 466-72	4	69
175	Triple-negative breast cancer: current management and future options. <i>European Journal of Cancer, Supplement</i> , 2009 , 7, 14-18	1.6	8
174	Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report. <i>Journal of Hematology and Oncology</i> , 2009 , 2, 35	22.4	6
173	Future role of bevacizumab in breast cancer. <i>Breast Cancer Research</i> , 2009 , 11,	8.3	78
172	Heterogeneity of multipotent mesenchymal stromal cells: from stromal cells to stem cells and vice versa. <i>Transplantation</i> , 2009 , 87, S36-42	1.8	56
171	Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation. <i>Blood</i> , 2009 , 114, 2333-43	2.2	159
170	Weekly low-dose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at second-look surgery after 6 cycles of paclitaxel/platinum-based chemotherapy: results of an open noncomparative phase 2 multicenter Italian study (After-6 Protocol 2). <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 615-9	3.5	12
169	Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature. <i>International Journal of Gynecological Cancer</i> , 2008 , 18, 943-53	3.5	21
168	Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial). <i>Clinical Breast Cancer</i> , 2008 , 8, 192-4	3	27

167	Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). <i>Clinical Breast Cancer</i> , 2008 , 8, 453-6	3	43
166	Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB). <i>Clinical Breast Cancer</i> , 2008 , 8, 97-100	3	14
165	Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. <i>Journal of Molecular Diagnostics</i> , 2008 , 10, 160-8	5.1	45
164	Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. <i>Oncologist</i> , 2008 , 13, 838-44	5.7	116
163	Donor cell-derived osteopoiesis originates from a self-renewing stem cell with a limited regenerative contribution after transplantation. <i>Blood</i> , 2008 , 111, 4386-91	2.2	47
162	Pulmonary strongyloidiasis mimicking cancer symptoms: a case of hyperinfection in a patient with metastatic lung cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008 , 31, 308-9	2.7	1
161	Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008 , 110, 127-34	4.4	16
160	Oral vinorelbine: role in the management of metastatic breast cancer. <i>Drugs</i> , 2007 , 67, 657-67	12.1	16
159	Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 68, 1455-61	4	91
158	Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective. <i>Breast Journal</i> , 2007 , 13, 28-35	1.2	43
157	Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. <i>Clinical Breast Cancer</i> , 2007 , 7, 841-9	3	12
156	Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. <i>British Journal of Cancer</i> , 2007 , 97, 1469-74	8.7	64
155	Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3399-406	2.2	250
154	Laparoscopic approach of gastric gastrointestinal stromal tumors (GISTs): is it still a courageous choice? Report of two cases. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2007 , 17, 133-7	1.3	4
153	Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives. <i>Cancer Letters</i> , 2007 , 248, 175-85	9.9	18
152	Controversies of chemotherapy for the treatment of metastatic breast cancer. <i>European Journal of Cancer, Supplement</i> , 2007 , 5, 11-16	1.6	2
151	Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria. <i>Pathology and Oncology Research</i> , 2006 , 12, 133-42	2.6	31
150	Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study. <i>Oncology</i> , 2006 , 71, 374-81	3.6	14

149	Primary systemic therapy in operable breast cancer: clinical data and biological fall-out. <i>Annals of Oncology</i> , 2006 , 17 Suppl 5, v158-64	10.3	23
148	Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. <i>Annals of Oncology</i> , 2006 , 17, 262-9	10.3	64
147	Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3912-8	2.2	74
146	Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. <i>Annals of Oncology</i> , 2006 , 17 Suppl 5, v118-22	10.3	81
145	Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I-II study. <i>British Journal of Cancer</i> , 2006 , 94, 1263-6	8.7	5
144	Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. <i>Cytotherapy</i> , 2006 , 8, 437-44	4.8	203
143	Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. <i>British Journal of Cancer</i> , 2006 , 94, 1016-20	8.7	31
142	Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy. <i>International Journal of Colorectal Disease</i> , 2006 , 21, 645-51	3	61
141	Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4265-74	2.2	1244
140	Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO). <i>Lung Cancer</i> , 2005 , 48, 121-7	5.9	7
139	Targeting the right chemotherapy for the right patient. <i>Breast Cancer Research</i> , 2005 , 7, 1	8.3	1
138	Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2005 , 55, 153-66	7	46
137	Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study. <i>British Journal of Cancer</i> , 2005 , 93, 406-11	8.7	15
136	High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2005 , 36, 25-31	4.4	10
135	Predictive value of biologic parameters for primary chemotherapy in operable breast cancer. <i>Clinical Breast Cancer</i> , 2005 , 6, 315-24	3	6
134	Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. <i>Cancer</i> , 2005 , 104, 1742-50	6.4	211
133	Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer. <i>Diseases of the Colon and Rectum</i> , 2005 , 48, 1851-7	3.1	55
132	In Response to Body Letter to the Editor Regarding Safety of Intravenous and Oral Bisphosphonates and Compliance with Dosing Regimens <i>Oncologist</i> , 2005 , 10, 318-319	5.7	2

131	Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , 2005 , 93, 35-40	8.7	55
130	Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. <i>Oncologist</i> , 2005 , 10, 842-8	5.7	73
129	The issue of renal safety of zoledronic acid from a nephrologist's point of view. <i>Oncologist</i> , 2005 , 10, 306-8; author reply 311-2	5.7	17
128	In Response to Jackson Letter to the Editor Regarding Safety of Intravenous and Oral Bisphosphonates and Compliance with Dosing Regimens <i>Oncologist</i> , 2005 , 10, 315-316	5.7	1
127	Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. <i>Oncologist</i> , 2004 , 9 Suppl 4, 28-37	5.7	172
126	Optimizing Bisphosphonate Therapy in Oncology. <i>Oncologist</i> , 2004 , 9, 1-2	5.7	2
125	HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support. <i>Bone Marrow Transplantation</i> , 2004 , 34, 413-414	4.7	9
124	Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. <i>British Journal of Cancer</i> , 2004 , 90, 31-5	8.7	65
123	Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy. <i>British Journal of Cancer</i> , 2004 , 90, 962-7	8.7	67
122	Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. <i>British Journal of Cancer</i> , 2004 , 90, 2112-7	8.7	67
121	Bisphosphonates in the treatment of skeletal metastases. <i>Seminars in Oncology</i> , 2004 , 31, 59-63	5.5	36
120	Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. <i>Cancer</i> , 2004 , 101, 704-12	6.4	103
119	5-fluorouracil administered as a 48-hour semiintermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004 , 27, 101-5	2.7	2
118	Isolation and Expansion of Functional Differentiating Mesenchymal Stem Cells with a Serum Deprived Medium.. <i>Blood</i> , 2004 , 104, 2852-2852	2.2	
117	Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). <i>Annals of Oncology</i> , 2003 , 14, 1365-72	10.3	24
116	First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients. <i>Gynecologic Oncology</i> , 2003 , 89, 354-9	4.9	16
115	High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. <i>Bone Marrow Transplantation</i> , 2003 , 31, 275-80	4.4	5
114	Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. <i>Annals of Oncology</i> , 2003 , 14, 227-32	10.3	54

113	Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1682-7	2.2	11
112	Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens. <i>Cancer</i> , 2002 , 95, 1444-50	6.4	34
111	Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations. <i>Genes Chromosomes and Cancer</i> , 2002 , 33, 235-42	5	93
110	Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. <i>European Journal of Clinical Pharmacology</i> , 2002 , 58, 593-5	2.8	14
109	Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2002 , 53, 508-18	3.8	38
108	Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. <i>Annals of Oncology</i> , 2002 , 13, 919-27	10.3	45
107	Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4006-14	2.2	130
106	Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 431-44	6.2	148
105	Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2002 , 3, 346-52		5
104	Bisphosphonates and Cancer: A Commentary. <i>Clinical Breast Cancer</i> , 2002 , 3, 217	3	3
103	Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients. <i>European Journal of Cancer</i> , 2002 , 38, 359-66	7.5	31
102	Pemetrexed: a promising new treatment for breast cancer. <i>Seminars in Oncology</i> , 2002 , 29, 36-41	5.5	89
101	Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. <i>Annals of Oncology</i> , 2001 , 12, 1301-6	10.3	84
100	Second-line treatment and consolidation therapies in advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2001 , 11 Suppl 1, 52-6	3.5	19
99	Advanced ovarian cancer in the elderly: results of consecutive trials with cisplatin-based chemotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2001 , 37, 27-34	7	15
98	Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. <i>Breast Cancer Research and Treatment</i> , 2001 , 68, 171-9	4.4	78
97	Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC). <i>British Journal of Cancer</i> , 2001 , 85, 1452-5	8.7	8
96	Increased prevalence of primary hyperparathyroidism in treated breast cancer. <i>Journal of Endocrinological Investigation</i> , 2001 , 24, 315-20	5.2	32

95	Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3456-62 ²	2.2	46
94	5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. <i>Oncology</i> , 2001 , 61, 28-35	3.6	8
93	High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). <i>Annals of Oncology</i> , 2001 , 12, 69-74	10.3	7
92	Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3068-77	2.2	1562
91	Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. <i>Annals of Oncology</i> , 2000 , 11, 1127-30	10.3	68
90	A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma. <i>Cancer</i> , 2000 , 89, 1714-9	6.4	18
89	Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2000 , 59, 133-9	4.4	22
88	Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. <i>Gynecologic Oncology</i> , 2000 , 76, 157-62	4.9	109
87	Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study. <i>Oncology</i> , 2000 , 59, 204-9	3.6	6
86	Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study. <i>Lung Cancer</i> , 2000 , 27, 75-80	5.9	79
85	Ambamustine in the second-line treatment of patients with small-cell lung cancer: a phase II Fonicap study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000 , 23, 22-5	2.7	7
84	Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000 , 23, 412-5	2.7	94
83	Infusions of fluorouracil and leucovorin: effects of the timing and semi-intermittency of drug delivery. <i>Oncology</i> , 1999 , 57, 195-201	3.6	18
82	Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3596-602	2.2	82
81	Intrahepatic Chemotherapy with Floxuridine, Leucovorin and Dexamethasone in Continuous Infusion and Mitomycin-c Bolus in Unresectable Hepatic Metastases from Colorectal Cancer: A Phase II Study. <i>Tumori</i> , 1999 , 85, 473-477	1.7	3
80	Up date in the management of advanced ovarian carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 1999 , 32, 49-58	7	25
79	Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 44, 159-63	3.5	13
78	Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. <i>Cancer</i> , 1999 , 86, 470-6	6.4	24

77	Paclitaxel/epirubicin/etoposide in patients with extensive-disease small-cell lung cancer (SCLC). <i>European Journal of Cancer</i> , 1999 , 35, S257-S258	7.5	2
76	Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer. <i>Clinical Pharmacokinetics</i> , 1999 , 37, 195-211	6.2	35
75	Epirubicin/vinorelbine as first line therapy in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 1998 , 49, 129-34	4.4	18
74	Radio-frequency thermal ablation of liver metastases with a cooled-tip electrode needle: results of a pilot clinical trial. <i>European Radiology</i> , 1998 , 8, 1205-11	8	165
73	Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. <i>British Journal of Cancer</i> , 1998 , 78, 1479-87	8.7	185
72	Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers. <i>European Journal of Cancer</i> , 1998 , 34, 1701-4	7.5	39
71	Pharmacokinetic optimisation of the treatment of cancer with high dose zidovudine. <i>Clinical Pharmacokinetics</i> , 1998 , 34, 173-80	6.2	8
70	Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells. <i>Annals of Oncology</i> , 1997 , 8, 533-45	10.3	15
69	Significance of lymph node sampling in epithelial carcinoma of the ovary. <i>Gynecologic Oncology</i> , 1997 , 65, 467-72	4.9	75
68	Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest. <i>Gynecologic Oncology</i> , 1997 , 65, 499-505	4.9	28
67	Anthracyclines-paclitaxel combinations in the treatment of breast cancer. <i>Annals of Oncology</i> , 1997 , 8, 939-43	10.3	12
66	Filgrastim and lack of support of intensive adjuvant chemotherapy for high-risk breast cancer patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997 , 20, 169-72	2.7	2
65	Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A randomized trial of the Gruppo Oncologico Nord Ovest (GONO). <i>Annals of Oncology</i> , 1996 , 7, 487-90	10.3	11
64	Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 1996 , 7, 747-9	10.3	15
63	Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase II study. <i>Annals of Oncology</i> , 1996 , 7, 857-60	10.3	10
62	Effects of primary chemotherapy on biological parameters of locally advanced breast cancer. <i>Annals of the New York Academy of Sciences</i> , 1996 , 784, 419-26	6.5	5
61	Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA-induced strand-breaks. <i>European Journal of Cancer</i> , 1996 , 32A, 1219-26	7.5	24
60	Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. <i>European Journal of Cancer</i> , 1996 , 32A, 1523-9	7.5	32

59	Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. <i>Journal of Clinical Oncology</i> , 1996 , 14, 2552-9	2.2	245
58	Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. <i>Journal of Clinical Oncology</i> , 1996 , 14, 729-36	2.2	18
57	Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. <i>Journal of Clinical Oncology</i> , 1996 , 14, 3112-20	2.2	128
56	Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 1996 , 14, 1858-67	2.2	313
55	High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. <i>Journal of Clinical Oncology</i> , 1996 , 14, 351-6	2.2	79
54	Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel. <i>Annals of Oncology</i> , 1996 , 7, 978-9	10.3	36
53	Tamoxifen and interferon-beta for the treatment of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 1996 , 39, 235-8	4.4	18
52	Twelve-year follow-up of a randomized trial comparing cisplatin and cyclophosphamide with cisplatin, doxorubicin and cyclophosphamide in patients with advanced epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 1996 , 6, 286-290	3.5	11
51	Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996 , 19, 78-81	2.7	6
50	Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996 , 19, 592-4	2.7	8
49	Interferon-alpha or beta potentiate platinum analogous in human glioblastoma cell lines. <i>Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1995 , 348, 131-5		4
48	Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. <i>Radiology</i> , 1995 , 197, 812-8 ^{20.5}		161
47	Long-term prognosis following macroscopic complete response at second-look laparotomy in advanced ovarian cancer patients treated with platinum-based chemotherapy. The Gruppo Oncologico Nord Ovest. <i>European Journal of Cancer</i> , 1995 , 31A, 296-301	7.5	18
46	Mitomycin-ifosfamide-cisplatin (MIP) vs MIP-interferon vs cisplatin-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force. <i>British Journal of Cancer</i> , 1995 , 71, 115-9	8.7	15
45	Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. <i>Cancer</i> , 1995 , 75, 440-3	6.4	14
44	Synergistic antiproliferative activity of suramin and alpha 2A-interferon against human colorectal adenocarcinoma cell lines: in vitro studies. <i>European Journal of Cancer</i> , 1994 , 30A, 516-20	7.5	6
43	Tumour kinetics, response to chemotherapy and survival in primary ovarian cancer. <i>European Journal of Cancer</i> , 1994 , 30A, 449-52	7.5	4
42	Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer. <i>European Journal of Cancer</i> , 1994 , 30A, 1432-5	7.5	27

41	Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma. <i>European Journal of Cancer</i> , 1994 , 30A, 338-43	7.5	21
40	High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1994 , 17, 72-6	2.7	50
39	Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma. GONO (North-West Oncologic Cooperative Group). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1994 , 17, 294-7	2.7	51
38	Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1994 , 17, 210-4	2.7	3
37	Recurrent ovarian carcinoma: salvage treatment with platinum in patients responding to first-line platinum-based regimens. <i>European Journal of Cancer</i> , 1993 , 29A, 652	7.5	1
36	The impact of received dose intensity on the outcome of advanced ovarian cancer. <i>European Journal of Cancer</i> , 1993 , 29A, 181-4	7.5	25
35	The role of lonidamine in the treatment of breast cancer patients. <i>Annals of the New York Academy of Sciences</i> , 1993 , 698, 349-56	6.5	4
34	Evaluation of taxol cardiotoxicity in metastatic breast cancer. <i>Annals of the New York Academy of Sciences</i> , 1993 , 698, 403-5	6.5	5
33	Analysis of time to response to chemotherapy in 316 metastatic breast cancer patients. <i>Oncology</i> , 1993 , 50, 460-5	3.6	2
32	Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study. <i>Cancer</i> , 1993 , 72, 564-8	6.4	8
31	Potential of TNF-mediated cell killing by mitoxantrone. Relationship to DNA single-strand break formation. <i>Biochemical Pharmacology</i> , 1993 , 46, 1199-206	6	9
30	Prediction of survival by thymidine labelling index in patients with resistant ovarian carcinoma. <i>European Journal of Cancer</i> , 1992 , 28A, 1079-80	7.5	3
29	Synergistic cytotoxic effects of recombinant human tumor necrosis factor and Etoposide (VP16) or Doxorubicin on A2774 human epithelial ovarian cancer cell line. <i>International Journal of Gynecological Cancer</i> , 1992 , 2, 147-151	3.5	4
28	Potential by tumor necrosis factor of mitoxantrone cytotoxicity to human ovarian cancer cell lines. <i>Japanese Journal of Cancer Research</i> , 1992 , 83, 684-7		5
27	Potential of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation. <i>Japanese Journal of Cancer Research</i> , 1992 , 83, 1132-6		13
26	Abdominopelvic radiotherapy following surgery and chemotherapy in advanced ovarian cancer. <i>Clinical Oncology</i> , 1991 , 3, 340-4	2.8	3
25	Effect of recombinant human tumor necrosis factor on A2774 human ovarian cancer cell line: potential of mitoxantrone cytotoxicity. <i>Gynecologic Oncology</i> , 1991 , 41, 52-5	4.9	15
24	Megestrol acetate: phase II study of a single daily administration in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 1990 , 17, 51-4	4.4	10

23	In vivo manipulation of human breast cancer growth by estrogens and growth hormone: kinetic and clinical results. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1990 , 37, 1103-8	5.1	8
22	Thymidine labelling index as prognostic factor in resected non-small cell lung cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1990 , 26, 622-5		19
21	Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. <i>Gynecologic Oncology</i> , 1990 , 38, 392-5	4.9	44
20	Crossover study with cisplatin or carboplatin in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 1990 , 39, 146-9	4.9	10
19	The role of surgery in the combined treatment of locally advanced breast cancer. <i>Oncology</i> , 1989 , 46, 353-6	3.6	6
18	Cell kinetics in ovarian cancer. Relationship to clinicopathologic features, responsiveness to chemotherapy, and survival. <i>Cancer</i> , 1989 , 64, 1188-91	6.4	21
17	Phase II study of lonidamine in metastatic breast cancer. <i>British Journal of Cancer</i> , 1989 , 59, 251-3	8.7	23
16	Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1989 , 12, 481-5	2.7	46
15	Evaluation of the ovarian cancer antigen, Ca-125, as a tumor marker. <i>Oncology</i> , 1989 , 46, 117-22	3.6	8
14	Cisplatin and 5-fluorouracil in refractory breast cancer patients: a phase II study. <i>Breast Cancer Research and Treatment</i> , 1988 , 11, 269-71	4.4	4
13	Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. <i>Breast Cancer Research and Treatment</i> , 1988 , 12, 307-10	4.4	115
12	Moving-strip abdomino-pelvic radiotherapy after cis-platinum-based chemotherapy and second-look operation. A feasibility study in advanced ovarian cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1988 , 11, 16-20	2.7	8
11	Uterine sarcomas: a clinicopathologic study. <i>Oncology</i> , 1988 , 45, 428-33	3.6	6
10	Tamoxifen rechallenge. <i>Journal of Clinical Oncology</i> , 1988 , 6, 751-2	2.2	2
9	Sequential administration of cyclophosphamide, methotrexate, 5-fluorouracil, and folinic acid as salvage treatment in metastatic breast cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1987 , 10, 404-6	2.7	7
8	A phase II study with danazol in metastatic breast cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1987 , 10, 407-9	2.7	7
7	Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: results of a randomized cooperative trial. <i>Journal of Clinical Oncology</i> , 1987 , 5, 339-47	2.2	59
6	Chemotherapy with estrogenic recruitment and surgery in locally advanced breast cancer: clinical and cytokinetic results. <i>International Journal of Cancer</i> , 1987 , 40, 490-4	7.5	45

5	Survival of patients with relapsing breast cancer: analysis of 302 patients. <i>Oncology</i> , 1986 , 43, 278-82	3.6	18
4	Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 1985 , 20, 290-7	4.9	26
3	Estrogen induced expansion of the growth fraction in receptor negative human breast cancer. <i>The Journal of Steroid Biochemistry</i> , 1985 , 23, 1169-72		6
2	Timed sequential chemotherapy following drug-induced kinetic recruitment in refractory ovarian cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1984 , 20, 1039-43		6
1	Early B lymphocytes in man. <i>Experientia</i> , 1980 , 36, 1124-5		3